Anlon Healthcare IPO Day 3: GMP, Subscription Status, Review – Should You Invest?

Sachin Jasuja of Centricity WealthTech said, “The space of API production is facing tailwinds due to ‘Make in India’ and Production Linked Incentive (PLI) schemes, which are driving domestic investment into API manufacturing and R&D, helping reduce import dependence and boost local capabilities. Policy support provides a cushion for API manufacturers through subsidies, capex support, and easier regulatory pathways, stimulating growth and improving margin stability.”

An Anlon Healthcare IPO Review helps investors assess risks and growth potential. Shivani Nyati with Swastika Investmart mentions that Anlon is the first Indian manufacturer of Loxoprofen formulations, globally compliant, but is susceptible to operational risks.

The company relies on a single facility in Rajkot, Gujarat, and faced revenue headwinds in FY24 due to registration delays in . Current IPO valuations seem fully priced, leaving little room for aggressive listing gains.